Alembic Pharmaceuticals Ltd
Fundamental Score
Alembic Pharmaceuticals Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of APLLTD across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (17.01%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Robust Profit Growth (28.80%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (15.91%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Conservative Debt Levels (D/E: 0.28)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (9.29x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹1236.03 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (69.74%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
2 factors identified
Weak Earnings Growth (-8.73% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-7.96% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Financial Statements
Comprehensive financial data for Alembic Pharmaceuticals Ltd
About APLLTD
Business Overview
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Company Details
Key Leadership
Corporate Events
APLLTD Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Alembic Pharmaceuticals Ltd (APLLTD)?
As of 21 Jan 2026, 08:44 am IST, Alembic Pharmaceuticals Ltd (APLLTD) is currently trading at ₹760.05. The stock has a market capitalization of ₹17.84K (Cr).
Is APLLTD share price Overvalued or Undervalued?
APLLTD is currently trading at a P/E ratio of 28.12x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Alembic Pharmaceuticals Ltd share price?
Key factors influencing APLLTD's price include its quarterly earnings growth (Sales Growth: 15.91%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Alembic Pharmaceuticals Ltd a good stock for long-term investment?
Alembic Pharmaceuticals Ltd shows a 5-year Profit Growth of -7.96% and an ROE of 11.38%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.28 before investing.
How does Alembic Pharmaceuticals Ltd compare with its industry peers?
Alembic Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare APLLTD's P/E of 28.12x and ROE of 11.38% against the industry averages to determine its competitive standing.
What is the P/E ratio of APLLTD and what does it mean?
APLLTD has a P/E ratio of 28.12x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹28 for every ₹1 of annual earnings.
How is APLLTD performing according to Bull Run's analysis?
APLLTD has a Bull Run fundamental score of 51/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does APLLTD belong to?
APLLTD operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Alembic Pharmaceuticals Ltd.
What is Return on Equity (ROE) and why is it important for APLLTD?
APLLTD has an ROE of 11.38%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Alembic Pharmaceuticals Ltd generates profits from shareholders' equity.
How is APLLTD's debt-to-equity ratio and what does it indicate?
APLLTD has a debt-to-equity ratio of 0.28, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is APLLTD's dividend yield and is it a good dividend stock?
APLLTD offers a dividend yield of 1.21%, which means you receive ₹1.21 annual dividend for every ₹100 invested.
How has APLLTD grown over the past 5 years?
APLLTD has achieved 5-year growth rates of: Sales Growth 7.69%, Profit Growth -7.96%, and EPS Growth -8.73%.
What is the promoter holding in APLLTD and why does it matter?
Promoters hold 69.74% of APLLTD shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is APLLTD's market capitalization category?
APLLTD has a market capitalization of ₹17841 crores, placing it in the Mid-cap category.
How volatile is APLLTD stock?
APLLTD has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for APLLTD?
APLLTD has a 52-week high of ₹N/A and low of ₹N/A.
What is APLLTD's operating profit margin trend?
APLLTD has a 5-year average Operating Profit Margin (OPM) of 17.01%, indicating the company's operational efficiency.
How is APLLTD's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 15.91% and YoY Profit Growth of 28.80%.
What is the institutional holding pattern in APLLTD?
APLLTD has FII holding of 4.04% and DII holding of 16.30%. Significant institutional holding often suggests professional confidence in the stock.